These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. CXCR4 expression in papillary thyroid carcinoma: induction by nitric oxide and correlation with lymph node metastasis. Yasuoka H; Kodama R; Hirokawa M; Takamura Y; Miyauchi A; Sanke T; Nakamura Y BMC Cancer; 2008 Sep; 8():274. PubMed ID: 18826577 [TBL] [Abstract][Full Text] [Related]
65. HLA class II expression in well differentiated thyroid carcinoma: correlation with clinicopathological features. Knoll MR; Schwab M; Oestreich K; Rumstadt B; Hagmüller E J Exp Clin Cancer Res; 1997 Jun; 16(2):177-82. PubMed ID: 9261744 [TBL] [Abstract][Full Text] [Related]
66. Valosin-containing protein (p97) and Ki-67 expression is a useful marker in detecting malignant behavior of pancreatic endocrine neoplasms. Yamamoto S; Tomita Y; Nakamori S; Hoshida Y; Iizuka N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Ishikawa O; Ohigashi H; Aozasa K; Monden M Oncology; 2004; 66(6):468-75. PubMed ID: 15452376 [TBL] [Abstract][Full Text] [Related]
67. Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma. Baek SK; Woo JS; Kwon SY; Lee SH; Chae YS; Jung KY Laryngoscope; 2007 May; 117(5):911-6. PubMed ID: 17473695 [TBL] [Abstract][Full Text] [Related]
68. Loss of Raf-1 kinase inhibitor protein expression is associated with lymph node metastasis in papillary thyroid cancer. Eun YG; Kim SW; Kim YW; Kwon KH Otolaryngol Head Neck Surg; 2010 Oct; 143(4):544-8. PubMed ID: 20869566 [TBL] [Abstract][Full Text] [Related]
69. The expression and role of serum response factor in papillary carcinoma of the thyroid. Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551 [TBL] [Abstract][Full Text] [Related]
70. S100A10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma. Ito Y; Arai K; Nozawa R; Yoshida H; Higashiyama T; Takamura Y; Miya A; Kobayashi K; Kuma K; Miyauchi A Anticancer Res; 2007; 27(4C):2679-83. PubMed ID: 17695432 [TBL] [Abstract][Full Text] [Related]
71. Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Falvo L; Giacomelli L; D'Andrea V; Marzullo A; Guerriero G; de Antoni E Am Surg; 2006 May; 72(5):438-44. PubMed ID: 16719201 [TBL] [Abstract][Full Text] [Related]
72. Clinical outcomes in older or younger patients with papillary thyroid carcinoma: impact of lymphadenopathy and patient age. Wada N; Masudo K; Nakayama H; Suganuma N; Matsuzu K; Hirakawa S; Rino Y; Masuda M; Imada T Eur J Surg Oncol; 2008 Feb; 34(2):202-7. PubMed ID: 18023321 [TBL] [Abstract][Full Text] [Related]
73. Minichromosome maintenance protein 3 is a candidate proliferation marker in papillary thyroid carcinoma. Lee YS; Ha SA; Kim HJ; Shin SM; Kim HK; Kim S; Kang CS; Lee KY; Hong OK; Lee SH; Kwon HS; Cha BY; Kim JW Exp Mol Pathol; 2010 Feb; 88(1):138-42. PubMed ID: 19818763 [TBL] [Abstract][Full Text] [Related]
74. Expression of lysyl oxidase is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Sakai M; Kato H; Sano A; Tanaka N; Inose T; Kimura H; Sohda M; Nakajima M; Kuwano H Ann Surg Oncol; 2009 Sep; 16(9):2494-501. PubMed ID: 19526206 [TBL] [Abstract][Full Text] [Related]